- Brain concussion injuries have commanded a new level of respect in recent years as military personnel, athletes and care center administrations seek remedies rather than simply encouraging people to “shake off” a hard hit to the head
- Odyssey Health is advancing clinical trials for its novel PRV-002 drug / device solution for treating concussion patients
- The company reported completion of four cohorts of testing for safety in human subjects in August, and is preparing to launch Phase II testing that will evaluate the product’s efficacy
- PRV-002 is administered intranasally where it can be taken up across the blood-brain barrier by the body, helping it to target the area where it is needed most with minimal expression in the blood’s circulation system
Medical solutions innovator Odyssey Health (OTC: ODYY) is preparing to launch Phase II clinical trial testing of its novel brain concussion therapy following successful outcomes in examining its drug’s safety.
Odyssey’s PRV-002 combines a synthetic neurosteroid with an intranasal applicator device to deliver the drug in such a way that it will be taken up into the brain with minimal circulation through the blood system. The drug is lipophilic, which helps it to cross the blood-brain barrier where it needs to go to…
NOTE TO INVESTORS: The latest news and updates relating to ODYY are available in the company’s newsroom at https://ibn.fm/ODYY
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to millions of social media followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.